platoseedplatoseed
Bioengineered kidneys for patients with kidney failure
We are developing an implantable therapeutic tissue that will be surgically delivered to patients suffering from end stage renal disease. Upon implantation, this tissue will supplement the patient's renal function, eliminating their dependency on dialysis and improving their disease status. This has the potential to not only get these patients off dialysis - a significant impact for them and their families - but to greatly extend the time required before kidney transplantation is essential.
Trestle Biotherapeutics is developing implantable bioengineered tissues aimed at treating end-stage renal disease and reducing dependence on dialysis. The company positions its approach as a novel stem cell-based therapeutic solution to kidney failure, with potential broader applicability to other organ failures. It emphasizes a mission to bridge disciplines and advance toward replacement organs through biofabrication and tissue engineering.
The company is developing implantable bioengineered tissues (bioengineered kidney/therapeutic tissue) intended for delivery to patients with end-stage renal disease (ESRD). The product aims to move patients off dialysis, delay transplantation, and eventually become replacement organs, leveraging stem cell biology, biofabrication, fluidics, and cell manufacturing to create implantable tissue therapies.
Who it’s for: Patients with kidney failure (ESRD) and related beneficiaries, including healthcare providers and research institutions interested in regenerative kidney therapies.
Founding team statements, leadership profiles, and mention of advisors/investors; early-stage R&D with stated development goals and upcoming updates
Co-founder, Chief Executive Officer. Dr. Shepherd is a vascular biologist, tissue engineer and regenerative medicine scientist by training. He has spent the past 10+ years in industry since leaving his academic position at the Yale School of Medicine. He has built successful research teams focused on using 3D bioprinting and biofabrication to develop both in vitro human tissue systems and translational approaches to creating therapeutic tissues.
Entrepreneur with 20+ years research experience in the fields of developmental biology, stem cell biology, and tissue engineering. Founded Trestle Biotherapeutics to develop a functional therapeutic tissue for patients suffering from Chronic Kidney Disease through the successful integration of stem cell biology and biofabrication.
Curative genetic medicines for kidney diseases
Replacing organ transplant with an infusion
